ES2166110T3 - Agonistas no alostericos de gabaa para tratar trastornos del sueño. - Google Patents

Agonistas no alostericos de gabaa para tratar trastornos del sueño.

Info

Publication number
ES2166110T3
ES2166110T3 ES98102355T ES98102355T ES2166110T3 ES 2166110 T3 ES2166110 T3 ES 2166110T3 ES 98102355 T ES98102355 T ES 98102355T ES 98102355 T ES98102355 T ES 98102355T ES 2166110 T3 ES2166110 T3 ES 2166110T3
Authority
ES
Spain
Prior art keywords
sleep disorders
alosteric
gabaa
agonists
treat sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98102355T
Other languages
English (en)
Inventor
Marike Lancel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166110(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2166110T3 publication Critical patent/ES2166110T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION TRATA DE UN PROCEDIMIENTO PARA TRATAR TRASTORNOS DEL SUEÑO EN UN PACIENTE QUE LO NECESITE, QUE INCLUYE LA ADMINISTRACION DE UNA CANTIDAD HIPNOTICAMENTE EFICAZ DE UN AGONISTA DE GABA A NO ALOSTERICO.
ES98102355T 1995-07-13 1996-07-10 Agonistas no alostericos de gabaa para tratar trastornos del sueño. Expired - Lifetime ES2166110T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Publications (1)

Publication Number Publication Date
ES2166110T3 true ES2166110T3 (es) 2002-04-01

Family

ID=7766768

Family Applications (3)

Application Number Title Priority Date Filing Date
ES98102356T Expired - Lifetime ES2166111T3 (es) 1995-07-13 1996-07-10 Uso de tiagabina para el tratamiento de trastornos del sueño.
ES98102355T Expired - Lifetime ES2166110T3 (es) 1995-07-13 1996-07-10 Agonistas no alostericos de gabaa para tratar trastornos del sueño.
ES96925704T Expired - Lifetime ES2165990T3 (es) 1995-07-13 1996-07-10 Thip para el tratamiento de trastornos del sueño.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES98102356T Expired - Lifetime ES2166111T3 (es) 1995-07-13 1996-07-10 Uso de tiagabina para el tratamiento de trastornos del sueño.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96925704T Expired - Lifetime ES2165990T3 (es) 1995-07-13 1996-07-10 Thip para el tratamiento de trastornos del sueño.

Country Status (12)

Country Link
US (1) US5929065A (es)
EP (3) EP0867184B1 (es)
JP (3) JP3754705B2 (es)
AT (3) ATE207349T1 (es)
AU (1) AU723954B2 (es)
CA (1) CA2226582C (es)
CL (1) CL2003002785A1 (es)
DE (4) DE19525598C2 (es)
DK (3) DK0840601T3 (es)
ES (3) ES2166111T3 (es)
PT (3) PT840601E (es)
WO (1) WO1997002813A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
ATE212550T1 (de) * 1997-08-01 2002-02-15 Elan Corp Plc Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
KR100785182B1 (ko) * 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
AU2002338855B2 (en) * 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
DE602004025808D1 (de) 2003-06-25 2010-04-15 Lundbeck & Co As H Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005023256A1 (en) * 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
DK1742624T3 (da) * 2004-02-18 2010-03-08 Sepracor Inc Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPHIC FORMS OF A GABAA AGONIST
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
PT3372229T (pt) 2014-06-06 2021-06-17 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a síndrome de angelman
LT3274331T (lt) 2015-03-24 2020-04-10 H. Lundbeck A/S 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas
PE20190338A1 (es) 2015-07-17 2019-03-07 Ovid Therapeutics Inc Metodos de tratamiento de trastornos del desarrollo con gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3122761A1 (en) 2018-12-14 2020-06-18 Raimondo Fazio Martial arts training device
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
WO2023015395A1 (en) * 2021-08-11 2023-02-16 Psyched Wellness Ltd. Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
EP0840601A1 (en) 1998-05-13
JPH11509194A (ja) 1999-08-17
DK0867178T3 (da) 2002-02-18
ATE207352T1 (de) 2001-11-15
US5929065A (en) 1999-07-27
AU723954B2 (en) 2000-09-07
EP0867178A1 (en) 1998-09-30
JP2005047925A (ja) 2005-02-24
DE69616375D1 (de) 2001-11-29
DE69616376T2 (de) 2002-06-27
DE19525598C2 (de) 1997-09-25
CL2003002785A1 (es) 2005-04-08
ES2166111T3 (es) 2002-04-01
WO1997002813A1 (en) 1997-01-30
DE69616376D1 (de) 2001-11-29
PT840601E (pt) 2002-04-29
DE19525598A1 (de) 1997-01-16
ATE207356T1 (de) 2001-11-15
DK0840601T3 (da) 2002-02-18
DE69616375T2 (de) 2002-07-11
ATE207349T1 (de) 2001-11-15
CA2226582C (en) 2008-02-19
PT867178E (pt) 2002-04-29
AU6613796A (en) 1997-02-10
EP0867184A1 (en) 1998-09-30
JP2009057382A (ja) 2009-03-19
DK0867184T3 (da) 2002-02-18
DE69616333T2 (de) 2002-07-04
DE69616333D1 (de) 2001-11-29
EP0867178B1 (en) 2001-10-24
ES2165990T3 (es) 2002-04-01
CA2226582A1 (en) 1997-01-30
PT867184E (pt) 2002-04-29
JP3754705B2 (ja) 2006-03-15
EP0840601B1 (en) 2001-10-24
EP0867184B1 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
ES2166110T3 (es) Agonistas no alostericos de gabaa para tratar trastornos del sueño.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR9912501A (pt) Tratamento de distúrbios hiperproliferativos
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DK0880350T3 (da) Behandling af dissemineret sklerose
EA200101089A1 (ru) Новый способ лечения
BR9714142A (pt) Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
EA199800866A1 (ru) Способ снятия боли
BR9612552A (pt) Processo para tratamento de autismo
DE69627298D1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
NO970607D0 (no) Anordning av selegilin i behandling av epileptiske tilstander
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
BR9708037A (pt) Método para o tratamento de abuso de substância
BR9612549A (pt) Método para tratamento de agressão excessiva
EA199800818A1 (ru) Способ лечения бессонницы
BR9709007A (pt) Uso de azaspirano substituìdo no tratamento da asma.
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
PA8435601A1 (es) Composiciones farmaceuticas y metodos de tratamiento de desordenes compulsivos usando inhibidores de naaladasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 867178

Country of ref document: ES